Lu-DOTATATE Plus Capecitabine Versus Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial.

Lu-DOTATATE has emerged as a viable treatment strategy for advanced well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Few retrospective studies have shown concomitant Lu-DOTATATE with radiosensitizing low-dose capecitabine to be effective in advanced NETs. However, this has not been validated in prospective randomized-controlled trials.

GTF2I acts as a novel tumor suppressor transcription factor and shows Favorable prognosis in renal cancer.

The role of GTF2I (General Transcription Factor2I) alteration has already been reported in thymic cancer as a valuable biomarker. However, the association of GTF2I mutation with renal cancer for prognosis of immunotherapy is not yet examined. The biologic and oncologic significance of GTF2I in renal cancer was examined at multiomics level such as mutation, copy number alteration, structural variants.

Self-management interventions for men with lower urinary tract symptoms: A systematic review and meta-analysis of randomized controlled trials.

Introduction: Lower urinary tract symptoms (LUTS) significantly impact men's quality of life and can cause bothersome symptoms, which often interfere with daily functioning and contribute to psychological distress. While pharmacological and surgical treatments are effective, they can have side effects, and not all men require or desire these interventions. The aim of this study is to assess the impact of self-management interventions on symptom severity.

Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma.

Background: Talquetamab (anti-G protein-coupled receptor family C group 5 member D) and teclistamab (anti-B-cell maturation antigen) are bispecific antibodies that activate T cells by targeting CD3 and that have been approved for the treatment of triple-class-exposed relapsed or refractory multiple myeloma.

Methods: We conducted a phase 1b-2 study of talquetamab plus teclistamab in patients with relapsed or refractory multiple myeloma. In phase 1, we investigated five dose levels in a dose-escalation study.

Phase transformation and metallurgical characterization of heat-treated nickel-titanium rotary instruments using differential scanning calorimetry, X-ray diffraction, and energy dispersive spectrometry.

Objective: The present study aimed to evaluate the phase transformation behavior and elemental analysis of thermomechanical-treated nickel-titanium (NiTi) rotary instruments, TruNatomy (Dentsply Sirona), HyFlex CM (coltene, Whaledent), and Neoendo Flex (Orikam healthcare India), using differential scanning calorimetry (DSC), X-ray diffraction (XRD), and energy dispersive X-ray spectrometry.

Materials And Methods: A total of 18 NiTi rotary instruments, TruNatomy, Hyflex CM, Neoendo Flex, taper. 04, size 25 (except TruNatomy, size 26) were selected and were divided into three groups ( = 6).